// App-Quantinova.ai

: Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)

Researchers

Presenter

  • Kimberly Snow Caroti

Principal Investigators

  • Khaled Abdelgawwad

  • George Psaroudakis

  • Marcela Rivera

  • Gunnar Brobert

  • Alexander T Cohen

  • Alok A Khorana

  • Cecilia Becattini

  • Agnes Y. Lee

  • Anders Ekbom

  • Marc Carrier

  • Craig I. Coleman

Medical Centers

  • University of British Columbia, Vancouver, Canada

  • School of Pharmacy, University of Connecticut, WEST SUFFIELD, CT

  • Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada

  • Thrombosis and Opthalmology, Bayer AG, Berlin, Germany

  • Internal Vascular and Emergency Medicine Stroke Unit, University of Perugia, Perugia, Italy

  • Hartford Hospital, Evidence-Based Practice Center, Hartford, CT

  • Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

  • Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

  • Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Solna, Sweden

Locations

  • Germany

  • Canada

  • United States

  • Sweden

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Brain cancer

  • Solid malignancies

Biomarkers

  • Catalase

Drug/Treatment

  • rivaroxaban

  • apixaban

  • Heparin

Outcome

  • N/A

Study Design

  • Active Comparator

  • Non Inferiority

  • Observational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved